在可手术的激素受体阳性乳腺癌患者中使用新辅助药物palbociclib
Takayuki Ueno1, Louis W C Chow2, Wonshik Han3
1Breast Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research (JFCR), Japan.
Endocrine-related cancer
|September 1, 2025
概括
将palbociclib添加到新辅助内分泌疗法 (NET) 并没有改善激素受体阳性,HER2阴性乳腺癌患者的结局. 该研究没有发现palbociclib和安慰剂组之间的有效性有显著差异.
科学领域:
- 癌症学
- 药理学
背景情况:
- 基因酶4/6 (CDK4/6) 抑制剂增强了乳腺癌内分泌治疗的疗效.
- 新辅助内分泌疗法 (NET) 是一种可手术,激素受体阳性,HER2阴性乳腺癌的治疗选择.
研究的目的:
- 评估在可手术,激素受体阳性,HER2阴性乳腺癌中添加palbociclib的疗效.
- 评估palbociclib对手术前内分泌预后指数 (PEPI) 和EndoPredict (EP) 临床风险评分的影响.
主要方法:
- 第三阶段随机双盲研究,涉及141名患者.
- 患者接受了16周的NET (乳醇或他莫西芬与卵巢功能抑制) 以及palbociclib或安慰剂.
- 其他主要终点:PEPI评分和EPclin风险评分.
主要成果:
- 在palbociclib和安慰剂组之间没有统计学上显著的PEPI得分差异 (p = 0. 563).
- 没有进行EPclin风险评分分析.
- 在Palbociclib组中,有9.7%的不良事件导致治疗中止,而在安慰剂组中为0%.
结论:
- 在研究的乳腺癌患者群体中,添加palbociclib并没有提高疗效.
- 没有发现新的安全问题,但由于不良事件而导致的停药率较高.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Hormonal Control of the Ovarian Cycle
2.7K
The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
2.7K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
259
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
259


